vs

Side-by-side financial comparison of Canaan Inc. (CAN) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $15.7M, roughly 1.3× Silence Therapeutics plc). Silence Therapeutics plc runs the higher net margin — -14.7% vs -18.4%, a 3.7% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

CAN vs SLN — Head-to-Head

Bigger by revenue
CAN
CAN
1.3× larger
CAN
$20.8M
$15.7M
SLN
Higher net margin
SLN
SLN
3.7% more per $
SLN
-14.7%
-18.4%
CAN

Income Statement — Q3 FY2025 vs Q1 FY2024

Metric
CAN
CAN
SLN
SLN
Revenue
$20.8M
$15.7M
Net Profit
$-3.8M
$-2.3M
Gross Margin
99.9%
82.2%
Operating Margin
-15.9%
-35.6%
Net Margin
-18.4%
-14.7%
Revenue YoY
Net Profit YoY
EPS (diluted)
$-0.05
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
SLN
SLN
Q4 25
$20.8M
Q3 25
$13.8M
Q2 25
$11.4M
Q3 24
$10.2M
Q2 24
$4.8M
Q1 24
$15.7M
Net Profit
CAN
CAN
SLN
SLN
Q4 25
$-3.8M
Q3 25
$-1.5M
Q2 25
$-11.9M
Q3 24
$-10.4M
Q2 24
$-5.4M
Q1 24
$-2.3M
Gross Margin
CAN
CAN
SLN
SLN
Q4 25
99.9%
Q3 25
99.9%
Q2 25
99.9%
Q3 24
99.9%
Q2 24
99.8%
Q1 24
82.2%
Operating Margin
CAN
CAN
SLN
SLN
Q4 25
-15.9%
Q3 25
-27.0%
Q2 25
-45.5%
Q3 24
-77.2%
Q2 24
-193.9%
Q1 24
-35.6%
Net Margin
CAN
CAN
SLN
SLN
Q4 25
-18.4%
Q3 25
-11.0%
Q2 25
-104.4%
Q3 24
-102.7%
Q2 24
-112.3%
Q1 24
-14.7%
EPS (diluted)
CAN
CAN
SLN
SLN
Q4 25
$-0.05
Q3 25
$-0.02
Q2 25
$-0.25
Q3 24
Q2 24
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$156.8M
Total Assets
$92.5M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Total Debt
CAN
CAN
SLN
SLN
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CAN
CAN
SLN
SLN
Q4 25
$52.4M
Q3 25
$44.7M
Q2 25
$33.8M
Q3 24
$43.6M
Q2 24
$56.8M
Q1 24
$156.8M
Total Assets
CAN
CAN
SLN
SLN
Q4 25
$92.5M
Q3 25
$81.7M
Q2 25
$78.0M
Q3 24
$69.3M
Q2 24
$73.7M
Q1 24
Debt / Equity
CAN
CAN
SLN
SLN
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
SLN
SLN
Operating Cash FlowLast quarter
$-9.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
SLN
SLN
Q4 25
Q3 25
Q2 25
Q3 24
Q2 24
Q1 24
$-9.1M
Capex Intensity
CAN
CAN
SLN
SLN
Q4 25
Q3 25
Q2 25
Q3 24
Q2 24
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons